Pitfalls in conducting prospective trials in stage III cardiac amyloidosis – experience from the REVEAL study-Reference-Cited by-同舟云学术

Pitfalls in conducting prospective trials in stage III cardiac amyloidosis – experience from the REVEAL study

Published:2017-10-02 Issue:4 Volume:24 Page:250-252
ISSN:1350-6129
Container-title:Amyloid
language:en
Short-container-title:Amyloid

Author:

Phillips Elizabeth H.¹,Nash Stephen¹,Adedayo Toyin¹,Whelan Carol J.²,Fontana Marianna²,Mahmood Shameem²,Lachmann Helen J.²,Gillmore Julian D.²,Smith Paul¹,Clifton-Hadley Laura¹,Hawkins Philip N.²,Wechalekar Ashutosh D.²

Affiliation:

1. Cancer Research UK and University College London Cancer Trials Centre, University College London, London, UK;

2. National Amyloidosis Centre, University College London, London, UK

Funder

Cancer Research UK

Publisher

Informa UK Limited

Subject

Internal Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13506129.2017.1385453

Reference10 articles.

1. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis

2. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

3. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis

4. A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis

5. Light chain amyloidosis: the heart of the problem

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience;ESMO Open;2021-04

2. Short tutorial. Treatment options in light chain amyloidosis and monoclonal gammopathy of renal significance;memo - Magazine of European Medical Oncology;2021-02-03